Literature DB >> 29087449

Monitoring resistance through liquid biopsy.

A R Parikh1,2, R B Corcoran1,2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29087449      PMCID： PMC6658708          DOI： 10.1093/annonc/mdx650

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  19 in total

1.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Sandra Misale; Rona Yaeger; Sebastijan Hobor; Elisa Scala; Manickam Janakiraman; David Liska; Emanuele Valtorta; Roberta Schiavo; Michela Buscarino; Giulia Siravegna; Katia Bencardino; Andrea Cercek; Chin-Tung Chen; Silvio Veronese; Carlo Zanon; Andrea Sartore-Bianchi; Marcello Gambacorta; Margherita Gallicchio; Efsevia Vakiani; Valentina Boscaro; Enzo Medico; Martin Weiser; Salvatore Siena; Federica Di Nicolantonio; David Solit; Alberto Bardelli
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

2.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Authors:  Giulia Siravegna; Benedetta Mussolin; Michela Buscarino; Giorgio Corti; Andrea Cassingena; Giovanni Crisafulli; Agostino Ponzetti; Chiara Cremolini; Alessio Amatu; Calogero Lauricella; Simona Lamba; Sebastijan Hobor; Antonio Avallone; Emanuele Valtorta; Giuseppe Rospo; Enzo Medico; Valentina Motta; Carlotta Antoniotti; Fabiana Tatangelo; Beatriz Bellosillo; Silvio Veronese; Alfredo Budillon; Clara Montagut; Patrizia Racca; Silvia Marsoni; Alfredo Falcone; Ryan B Corcoran; Federica Di Nicolantonio; Fotios Loupakis; Salvatore Siena; Andrea Sartore-Bianchi; Alberto Bardelli
Journal:  Nat Med       Date:  2015-06-01       Impact factor: 53.440

Review 3.  The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Authors:  Christina Therkildsen; Troels K Bergmann; Tine Henrichsen-Schnack; Steen Ladelund; Mef Nilbert
Journal:  Acta Oncol       Date:  2014-03-25       Impact factor: 4.089

Review 4.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution.

Authors:  Nicholas McGranahan; Charles Swanton
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

5.  Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Authors:  Lipika Goyal; Supriya K Saha; Leah Y Liu; Giulia Siravegna; Ignaty Leshchiner; Leanne G Ahronian; Jochen K Lennerz; Phuong Vu; Vikram Deshpande; Avinash Kambadakone; Benedetta Mussolin; Stephanie Reyes; Laura Henderson; Jiaoyuan Elisabeth Sun; Emily E Van Seventer; Joseph M Gurski; Sabrina Baltschukat; Barbara Schacher-Engstler; Louise Barys; Christelle Stamm; Pascal Furet; David P Ryan; James R Stone; A John Iafrate; Gad Getz; Diana Graus Porta; Ralph Tiedt; Alberto Bardelli; Dejan Juric; Ryan B Corcoran; Nabeel Bardeesy; Andrew X Zhu
Journal:  Cancer Discov       Date:  2016-12-29       Impact factor: 39.397

Review 6.  Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.

Authors:  Daniel A Haber; Victor E Velculescu
Journal:  Cancer Discov       Date:  2014-05-06       Impact factor: 39.397

7.  Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.

Authors:  Mariangela Russo; Giulia Siravegna; Lawrence S Blaszkowsky; Giorgio Corti; Giovanni Crisafulli; Leanne G Ahronian; Benedetta Mussolin; Eunice L Kwak; Michela Buscarino; Luca Lazzari; Emanuele Valtorta; Mauro Truini; Nicholas A Jessop; Hayley E Robinson; Theodore S Hong; Mari Mino-Kenudson; Federica Di Nicolantonio; Ashraf Thabet; Andrea Sartore-Bianchi; Salvatore Siena; A John Iafrate; Alberto Bardelli; Ryan B Corcoran
Journal:  Cancer Discov       Date:  2015-12-07       Impact factor: 39.397

8.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

9.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

10.  Absolute quantification of somatic DNA alterations in human cancer.

Authors:  Scott L Carter; Kristian Cibulskis; Elena Helman; Aaron McKenna; Hui Shen; Travis Zack; Peter W Laird; Robert C Onofrio; Wendy Winckler; Barbara A Weir; Rameen Beroukhim; David Pellman; Douglas A Levine; Eric S Lander; Matthew Meyerson; Gad Getz
Journal:  Nat Biotechnol       Date:  2012-05       Impact factor: 54.908
View more
  2 in total

1.  The need for rapid therapeutic efficacy testing for cancer therapy.

Authors:  David G Kaufman
Journal:  Exp Mol Pathol       Date:  2020-01-23       Impact factor: 4.401

Review 2.  Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

Authors:  Fiorella Calabrese; Federica Pezzuto; Francesca Lunardi; Francesco Fortarezza; Sofia-Eleni Tzorakoleftheraki; Maria Vittoria Resi; Mariaenrica Tiné; Giulia Pasello; Paul Hofman
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.